Milestone Scientific, Inc. · AMEX:MLSS
Milestone Scientific — Investor Presentation (September 2024)
14 slides from Milestone Scientific's investor presentation, September 2024
Slide 1: Delivering Precise, Pain-Free Injections
Delivering Precise, Pain-Free Injections (NYSE: MLSS) Shares Outstanding: 77.3m Price 9/25/24: $0.99 Market Capitalization: $76.5M Cash (Q2 6/30/2024): $5.8M Debt: $0 Insider Ownership: 25% September 2024
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements regarding events, conditions and financial trends, including the timing an d financial impact of Milestone's ability to implement its business plan, expected revenues and timing of regulatory approvals, that may affect Milesto
Slide 3: Executive Summary
Executive Summary Innovative Injection Technology: Patented, computer-controlled systems for precise, efficient, and safe medical and dental injections. Dynamic Pressure Sensing Technology®: Regulates flow rate and measures pressure for next-gen devices, with applications in drug delivery and anesthes
Slide 4: Problem: Placing Epidurals Can be Challenging
Problem: Placing Epidurals Can be Challenging Needle placement 17% Epidural Dural is difficult failure rates punctures are high Requires 60 placements Requires re-placement Up to 5+% in the lumbar before adequate skill of epidural 5 region, and 17% and 30% for level reached4 the thoracic and cervical
Slide 5: Solution: Introducing CompuFlo Epidural System
Solution: Introducing CompuFlo® Epidural System A New Standard of Care in Anesthesia Tackling the vast epidural market | Technology for precise needle placement and verification in epidural anesthesia INVESTOR PRESENTATION 5
Slide 6: Solution: CompuFlo Epidural System
Solution: CompuFlo® Epidural System Advanced innovation in the anesthesiology market = A New Standard of Care FDA cleared for use in lumbar, thoracic, and cervical -thoracic junction of the spine (Feb. 2023) Patented CompuWave and CathCheck Verification System allow anesthesiologists to save significa
Slide 7: Opportunity: Millions Seeking Chronic Back Pain Relief
Opportunity: Millions Seeking Chronic Back Pain Relief Epidurals for chronic back pain = One of the fastest growing procedures in the US and worldwide US Overall ESI Market ($2B) 9 million Epidural Steroid Injections (ESI) performed annually in the U.S. o Represents a $2 billion market Medicare acco
Slide 8: Medicare Reimbursement Expansion for CompuFlo Epidural System
Medicare Reimbursement Expansion for CompuFlo® Epidural System Medicare Payment Rate Granted in 3 Jurisdictions Near-term Target Markets (as of July 23, 2024) Covering 30% of Medicare ESI Procedures: Initial target market o Jurisdiction N (JN): Florida, Virgin Islands, Puerto Rico 12% o Jurisdiction
Slide 9: Benefits of Medicare Reimbursement
Benefits of Medicare Reimbursement Increased Accessibility More patients can benefit from safer, more comfortable epidural procedures Enhanced Patient Outcomes CompuFlo® reduces the risk of complications, leading to better patient outcomes + higher satisfaction Support for Healthcare Providers Provide
Slide 10: Growing Distribution
Growing Distribution Strategic Partnership with Axial Biologics to Distribute CompuFlo® in New Jersey, Texas, and Florida Jurisdictions Recent Medicare Company has a vast network of pain management doctors Price Assignment is, 30+ salespeople in the field “positioning CompuFlo® to disrupt the market
Slide 11: Beyond Epidural: Future Growth Opportunities
Beyond Epidural: Future Growth Opportunities Epidural During Labor and Delivery: 2.4M procedures per year More than 50% of women giving birth in the US use an epidural for pain relief Subsequent catheter checks can add 750K procedures Specific Addressable Market >$1B in Peripheral Nerve Block: the US
Slide 12: Milestone Scientific: Proven Success Minimizing Injection Pain
Milestone Scientific: Proven Success Minimizing Injection Pain Leading developer of computerized drug delivery devices providing virtually painless + precise injections $2B high-margin recurring revenue opportunity FDA approved product CompuFlo® (Feb 2023) 20+ years of patent protection Expanding rei
Slide 13: The Team
The Team Eric C. Hines Mark Hochman, D.D.S. James Hippett, J.D. Keisha Harcum, M.B.A., M.S. CEO Clinical Director SVP, Global Sales & VP of Finance Business Development Eric C. Hines is a seasoned high-tech Dr. Hochman is a multi -trained specialist A British native, Mr. Hip pett has an H onors Law
Slide 14: Thank you
Eric C. Hines, CEO Thank you EHines@milestonescientific.com milestonescientific.com
Milestone Scientific — Investor Presentation (September 2024) on 6ix